Interim results from the EQUATE Study: Preliminary safety and efficacy of itolizumab, a novel targeted anti-CD6 therapy, in newly diagnosed severe acute graft-versus-host disease

John Koreth, et. al., 2021

European Hematology Association (EHA) Virtual Congress 2021
06/10/2021/by David Anderson

Validation of a Whole Blood and Proteomic Stabilized Blood Assay to Monitor the Engagement and Modulation of CD6 on T cells by Itolizumab as a Clinical Pharmacodynamic Biomarker in Autoimmune Diseases

Lynn Kisselbach, et. al., 2021

CYTO Virtual Interactive Meeting 2021
06/10/2021/by David Anderson

Blockade of the CD6-ALCAM pathway modulates effector T cell function

Jeanette Ampudia, et. al., 2021

American Association of Immunologists (AAI) Annual Meeting 2021
05/14/2021/by eallison

Itolizumab-induced Antigenic Modulation of CD6 Inhibits T Cell Activity

Dalena Chu, et. al., 2021

American Association of Immunologists (AAI) Annual Meeting 2021
05/10/2021/by eallison

An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab

Angelina Bisconte, et. al., 2021

American Association of Immunologists (AAI) Annual Meeting 2021
05/10/2021/by eallison

Preliminary safety and efficacy of itolizumab, a novel targeted anti-cd6 therapy, in newly diagnosed severe acute graft-versus-host disease: interim results from the equate study

John Koreth, et. al., 2021

European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2021
03/12/2021/by eallison

Early reconstitution of cd6+ t cells after hematopoietic cell transplantation identifies a suitable target for acute graft-versus-host disease treatment using anti-cd6 monoclonal antibody itolizumab

Benedetta Rambaldi et. al., 2021

European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2021
03/12/2021/by eallison

Preliminary Safety and Efficacy of Itolizumab, A Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Severe Acute Graft-Versus-Host Disease: Interim Results from Equate Study

John Koreth et. al., 2021

TCT Meetings Digital Experience 2021
02/10/2021/by eallison

Impact of Itolizumab on the Expression of CD6 and the Function of Effector T Cells

Jeanette Ampudia et. al., 2020

American Society of Hematology Annual Meeting December 2020
12/05/2020/by David Anderson

Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab

Benedetta Rambaldi et. al., 2020

American Society of Hematology Annual Meeting December 2020
12/05/2020/by David Anderson

CD6-ALCAM Pathway is Elevated in Patients with Severe Asthma

Manali Mukherjee et. al., 2020

European Respiratory Society International Congress September 2020
09/18/2020/by eallison

CD6 Is Highly Expressed In Fatal Asthma Patients and May Modulate Bronchomotor Tone

Cynthia J. Koziol-White et. al., 2020

European Respiratory Society International Congress September 2020
09/18/2020/by eallison

CD6 Is Expressed On Human Airway and Blood ILCs and Is Upregulated by Epithelial Alarmins IL-33 and TSLP

Jana Badrani et. al., 2020

European Respiratory Society International Congress September 2020
09/18/2020/by eallison

CD6-ALCAM Signaling Regulates Multiple Effector/Memory T Cell Functions

Jeanette Ampudia et. al., 2020

American Association for Immunologists Conference May 2020
09/18/2020/by eallison

CD6 Modulation Ameliorates Immune Complex-Mediated Glomerulonephritis

Samantha A. Chalmers et. al., 2020

American Association for Immunologists Conference May 2020
09/18/2020/by eallison

Amelioration of Skin and Kidney Disease in a Spontaneous Murine Lupus Model via CD6 Modulation

Samantha A. Chalmers et. al., 2020

American Association for Immunologists Conference May 2020
09/18/2020/by eallison

Targeting the CD6-ALCAM Pathway to Prevent and Treat Graft vs Host Disease

Cherie Ng et. al., 2020

Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy & the Center for International Blood & Marrow Transplant Research February 2020
09/18/2020/by eallison

Itolizumab May Have Broad Therapeutic Potential

Krishna Polu, M.D.
Chief Medical Officer
2020
01/23/2020/by eallison

The Role of T Cells in Health and Disease

Stephen Connelly, Ph.D.
Chief Scientific Officer
2020
01/21/2020/by David Anderson

The Role of CD6-ALCAM Signaling in Autoimmunity

Stephen Connelly, Ph.D.
Chief Scientific Officer
2020
01/16/2020/by David Anderson

The CD6-ALCAM Pathway Maybe a Predictive Biomarker in Patients with Lupus Nephritis

Krishna Polu, M.D.
Chief Medical Officer
2020
01/21/2020/by David Anderson

What Would You Say to an Individual Who is Newly Diagnosed with Lupus

Ellen H.
Lupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
01/21/2020/by David Anderson

The Pathogenesis of Lupus

Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/21/2020/by David Anderson

Itolizumab Uniquely Modulates Both the Activity and Trafficking of T Effector Cells

Krishna Polu, M.D.
Chief Scientific Officer
2020
01/21/2020/by David Anderson

Lupus is a Highly Heterogeneous Disease, No Two Patients Are Alike

Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/21/2020/by David Anderson

The Need For a Personalized Approach in Treating Lupus Nephritis

Krishna Polu, M.D.
Chief Medical Officer
2020
01/21/2020/by David Anderson

The Path to Diagnosis and the Journey of Lupus

Ellen H.
Lupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
01/21/2020/by David Anderson

The Importance of Participating in Clinical Trials

Ellen H.
Lupus and Lupus Nephritis Patient
&
Courtney W.
Lupus Patient
2020
01/16/2020/by David Anderson

Why it’s Important to Consider Clinical Trial Participation

Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/16/2020/by David Anderson

Working Towards a Brighter Future for Individuals with Lupus and Lupus Nephritis

Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/16/2020/by David Anderson

What is the Current Treatment Approach for Patients with Lupus Nephritis?

Ken Kalunian, M.D.
Professor in the Division of Rheumatology, Allergy and Immunology in the School of Medicine at UC San Diego
2020
01/16/2020/by David Anderson

The Clinical Implications of Lupus Nephritis

Krishna Polu, M.D.
Chief Medical Officer
2020
12/19/2019/by David Anderson

EQUATE, a Phase 1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of a novel targeted anti-CD6 therapy, itolizumab, in subjects with newly diagnosed acute graft versus host disease

John Koreth et. al., 2019

American Society of Hematology Annual Meeting December 2019
09/18/2020/by eallison

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation After In Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Benedetta Rambaldi, MD et. al., 2019

American Society of Hematology Annual Meeting December 2019
09/18/2020/by eallison

Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease

Ng et al., 2019. Blood, 134:5603
12/30/2019/by David Anderson

Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation

Samantha A. Chalmers et. al., 2019

American College of Rheumatology Annual Meeting November 2019
09/18/2020/by eallison

CD6 Inhibition Prevents Skin and Kidney Disease in a Spontaneous Murine Model of SLE

Samantha A. Chalmers et. al., 2019

American College of Rheumatology Annual Meeting November 2019
09/18/2020/by eallison

Clinical and experimental evidence for targeting CD6 in immune-based disorders

Consuerga-Fernandez et al., 2018. Autoimmune Rev.
12/30/2019/by eallison

Activated leucocyte cell adhesion molecule (ALCAM/CD166) regulates T cell responses in a murine model of food allergy

Kim et al., 2018 192: 151-164.
12/30/2019/by eallison

Activated Leukocyte Cell Adhesion Molecule Stimulates the T-Cell Response in Allergic Asthma

Kim et al., 2018. American Journal of Respiratory and Critical Care Medicine. 197(8)
12/30/2019/by eallison

Failure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation

Meyer & Kofler, 2018. Cellular and Molecular Immunology.
12/30/2019/by eallison

The role of CD6 in autoimmune diseases

Fox, 2018.  Cellular & Molecular Immunology.
12/30/2019/by eallison

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

Bughani et al., 2018. PLoS One. 12(7): e0180088
12/30/2019/by eallison

CD6 as a potential target for treating multiple sclerosis

Li et al, 2017. PNAS. 114(10): 2687-2692.
12/30/2019/by eallison

Targeting CD6 for the treatment of experimental autoimmune uveitis

Zhang et al., 2017. Journal of Autoimmunity.
12/30/2019/by eallison

T Cell Costimulation by CD6 is Dependent on Bivalent Binding of a GADS/SLP-76 Complex

Breuning & Brown, 2017. Molecular and Cellular Biology.
12/30/2019/by eallison

Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis

Consuerga-Fernandez et al., 2017. Cellular and Molecular Immunology. 14: 1-9.
12/30/2019/by eallison

Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance

Consuerga-Fernandez et al., 2017. Frontiers in Immunology.
12/30/2019/by eallison

CD6 modulates thymocyte selection and peripheral T cell Homeostasis

Orta-Mascar et al., 2016. Journal of Experimental Medicine. 213(8): 1387-1397.
12/30/2019/by eallison

Itolizumab – a humanized, anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis

Roshni & Brinda, 2015. Clinical, Cosmetic and Investigational Dermatology. 8: 215-222.
12/30/2019/by eallison

Human Treg cells are characterized by low/negative CD6 expression

Garcia Santana et al., 2014. Cytrometry A. 85(10): 901-908.
12/30/2019/by eallison

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind randomized, placebo-controlled, phase-III study

Krupashnkar et al., 2014. J Am Acad Dermatol. 71(3): 484-492.
12/30/2019/by eallison

A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation

Khatri et al., 2013 The Journal of Experimental Medicine 210 (11) 2205-2221
12/30/2019/by eallison

CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction

Nair et al., 2010 Clinical and Experimental Immunology. 162: 116–130
12/30/2019/by eallison

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

Zimmerman et al., 2006. Blood 107(8): 3212-3220.
12/30/2019/by eallison

Relevance of CD6-mediated interactions in T cell activation and proliferation

Gimferrer et al., 2004. J Immunol 173(4): 2262-2270.
12/30/2019/by eallison

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow

Soiffer et al., 1992. J Clin Oncol 10(7): 1191-1200.
12/30/2019/by eallison